Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383747 · ClinicalTrials.gov registry record · Phase 4
The Effects of Nicotine on Cognition in Schizophrenia
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00383747: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00383747 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00383747, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We will evaluate the effects of transdermal nicotine compared with placebo for attentional impairments in non-smokers with schizophrenia and controls.
Interventions
- DRUG Transdermal Nicotine Patch
- DRUG transdermal nicotine patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00383747
The ClinicalTrials.gov registry entry for NCT00383747 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transdermal Nicotine Patch is the first listed.
NCT00383747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00383747 about?
NCT00383747 is a clinical study titled "The Effects of Nicotine on Cognition in Schizophrenia". Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We will evaluate the effects of transdermal nicotine compared with placebo ...
What is the current status of trial NCT00383747?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2004-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00383747?
The interventions under investigation include: Transdermal Nicotine Patch (DRUG), transdermal nicotine patch (DRUG).
Who is sponsoring clinical trial NCT00383747?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.